Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) was up 6.43% this morning to $24.33 as a PDUFA decision date of October 30 for the company’s drug, AVP-923, draws close, implying potential FDA approval. At 8:35 AM EST Avanir had already traded 4,600 shares, compared with the company’s average of 1,527,350. This move comes during a 52-week range of $1.65 to $3.73.
AVP-923 is usedfor the treatment of psuedobulbar affect in patients with amyotrophic lateral sclerosis and multiple sclerosis.
-Michael B. Sauter